Literature DB >> 19889649

An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study.

Peter Barlis1, Evelyn Regar, Patrick W Serruys, Konstantinos Dimopoulos, Willem J van der Giessen, Robert-Jan M van Geuns, Giuseppe Ferrante, Simon Wandel, Stephan Windecker, Gerrit-Anne van Es, Pedro Eerdmans, Peter Jüni, Carlo di Mario.   

Abstract

AIMS: Incomplete endothelialization has been found to be associated with late stent thrombosis, a rare but devastating phenomenon, more frequent after drug-eluting stent implantation. Optical coherence tomography (OCT) has 10 times greater resolution than intravascular ultrasound and thus appears to be a valuable modality for the assessment of stent strut coverage. The LEADERS trial was a multi-centre, randomized comparison of a biolimus-eluting stent (BES) with biodegradable polymer with a sirolimus-eluting stent (SES) using a durable polymer. This study sought to evaluate tissue coverage and apposition of stents using OCT in a group of patients from the randomized LEADERS trial. METHODS AND
RESULTS: Fifty-six consecutive patients underwent OCT during angiographic follow-up at 9 months. OCT images were acquired using a non-occlusive technique at a pullback speed of 3 mm/s. Data were analysed using a Bayesian hierarchical random-effects model, which accounted for the correlation of lesion characteristics within patients and implicitly assigned analytical weights to each lesion depending on the number of struts observed per lesion. Primary outcome was the difference in percentage of uncovered struts between BESs and SESs. Twenty patients were included in the analysis in the BES group (29 lesions with 4592 struts) and 26 patients in the SES group (35 lesions with 6476 struts). A total of 83 struts were uncovered in the BES group and 407 out of 6476 struts were uncovered in the SES group [weighted difference -1.4%, 95% confidence interval (CI) -3.7 to 0.0, P = 0.04]. Results were similar after adjustment for pre-procedure lesion length, reference vessel diameter, number of implanted study stents, and presence of stent overlap. There were three lesions in the BES group and 15 lesions in the SES group that had > or =5% of all struts uncovered (difference -33.1%, 95% CI -61.7 to -10.3, P < 0.01).
CONCLUSION: Strut coverage at an average follow-up of 9 months appears to be more complete in patients allocated to BESs when compared with SESs. The impact of this difference on clinical outcome and, in particular, on the risk of late stent thrombosis is yet to be determined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889649     DOI: 10.1093/eurheartj/ehp480

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  50 in total

1.  Should we rely on OCT to assess the improvements of new generation drug-eluting stents?

Authors:  Pedro A Lemos
Journal:  Int J Cardiovasc Imaging       Date:  2011-11-01       Impact factor: 2.357

2.  The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study.

Authors:  Miodrag C Ostojic; Zoran Perisic; Dragan Sagic; Robert Jung; Yan-Ling Zhang; Jamie Bendrick-Peart; Ronald Betts; Uwe Christians
Journal:  Eur J Clin Pharmacol       Date:  2010-10-09       Impact factor: 2.953

3.  Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial.

Authors:  Pasi Karjalainen; Tuomas O Kiviniemi; Tuomas Lehtinen; Wail Nammas; Antti Ylitalo; Antti Saraste; Jussi Mikkelsson; Mikko Pietila; Fausto Biancari; Juhani K E Airaksinen
Journal:  Int J Cardiovasc Imaging       Date:  2013-08-31       Impact factor: 2.357

4.  One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India.

Authors:  Ashwin B Mehta; Praveen Chandra; Jamshed Dalal; Prabhakar Shetty; Devang Desai; K Chocklingam; Jayesh Prajapati; Pramod Kumar; Vilas Magarkar; Apurva Vasawada; B K Goyal; Viveka Kumar; V Suryaprakash Rao; Ramesh Babu; Pritesh Parikh; Upendra Kaul; Aruna Patil; Tushar Mhetre; Hrishikesh Rangnekar
Journal:  Indian Heart J       Date:  2013-09-23

5.  Clinical outcomes with Biolimus (A9)™ eluting stent, 'BioMatrix' in diabetic patients--interim results from multicenter post market surveillance registry in India.

Authors:  Ashok Seth; Shirish Hiremath; Sameer Dani; Sunil Kapoor; R K Jain; Rajpal Abhaichand; Shailendra Trivedi; Upendra Kaul; Aruna Patil; Bhushan Khemnar; Hrishikesh Rangnekar
Journal:  Indian Heart J       Date:  2013-09-21

Review 6.  Nanotechnology in diagnosis and treatment of coronary artery disease.

Authors:  Mahdi Karimi; Hossein Zare; Amirala Bakhshian Nik; Narges Yazdani; Mohammad Hamrang; Elmira Mohamed; Parham Sahandi Zangabad; Seyed Masoud Moosavi Basri; Leila Bakhtiari; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2016-02-23       Impact factor: 5.307

7.  Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography.

Authors:  Tomohisa Tada; Adnan Kastrati; Robert A Byrne; Tibor Schuster; Rezarta Cuni; Lamin A King; Salvatore Cassese; Michael Joner; Jürgen Pache; Steffen Massberg; Albert Schömig; Julinda Mehilli
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-23       Impact factor: 2.357

Review 8.  Recent developments in drug-eluting stents.

Authors:  Yue Li; Ravinay Bhindi; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2011-01-29       Impact factor: 4.599

Review 9.  Causes, assessment, and treatment of stent thrombosis--intravascular imaging insights.

Authors:  Daniel S Ong; Ik-Kyung Jang
Journal:  Nat Rev Cardiol       Date:  2015-03-17       Impact factor: 32.419

10.  Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography.

Authors:  Rodolfo Staico; Marco A Costa; Daniel Chamié; Hiram Bezerra; Luciana V Armaganijan; Ricardo A Costa; José Ribamar Costa; Dimytri Siqueira; Marinella Centemero; Áurea Chaves; Luiz Fernando Tanajura; Alexandre Abizaid; Fausto Feres; J Eduardo M R Sousa; Amanda G M R Sousa
Journal:  Int J Cardiovasc Imaging       Date:  2013-03-03       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.